Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at firstname.lastname@example.org if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Posted 01 November 2013 | By Alexander Gaffney, RAC,
The European Medicines Agency (EMA) has announced the release of a new concept paper calling for the revision of its guideline on the development of products intended to treat Alzheimer's disease "and other dementias," saying a new approach is needed to accommodate patients who are pre-symptomatic or in the early stages of disease progression.
The concept paper is similar to a draft guidance released in February 2013 by the US Food and Drug Administration (FDA), which also noted the need to support treatments intended to prevent the onset of overt dementia.
"The underlying anatomical and pathophysiologic changes in AD begin many years before clinical symptoms emerge," FDA explained. "We recognize that the standard approaches to the selection of outcome measures historically used in the development of treatments for dementia of the Alzheimer's type have major limitations when applied to clinical trials enrolling patients in the early clinical stages of the disease, or before clinical impairment has emerged at all."
EMA seems to agree with that assessment, at least in theory. "[P]opulations of early and even pre-symptomatic patients are being included in clinical development programs," it wrote. "The inclusion of prodromal patients might enable treating individuals, hypothetically, at a time when some drugs may be more effective than they would be later in the illness. These changes need consideration in a revision of the current AD guidance as e.g. assessment tools need to be more sensitive and the requirement of two co-primary endpoints addressing improvement of cognition and functional activities of daily living is not feasible in in such a patient population."
Similar to FDA, EMA said the biggest challenge of all seems to be the correct utilization of diagnostic criteria, particularly at early stages of the disease when it can be difficult to measure outcomes. EMA said it hopes that new research diagnostic criteria, biomarkers and outcome measures can be used by companies to satisfy regulators' safety and efficacy concerns.
Regulators also said any future guideline should take into account the use of different parameters and assessment tools in different stages of the disease, different assessments of safety and efficacy in different age groups, the design of long-term safety studies, and the usefulness of combination therapy and how those therapies should be studied.
An updated guidance should be available within six months of the adoption of the concept paper, EMA wrote. Comments on the draft are due by 31 January 2014.
EMA Draft Concept Paper
EMA Press Statement
Tags: Alzheimer's Disease, Ad, EU
Regulatory Focus newsletters
All the biggest regulatory news and happenings.